Comment on "The matrix metalloproteinases as pharmacological target in osteoarthritis: Statins may be of therapeutic benefit"

Medical Hypotheses

Volumn 74, Issue 2, 2010, Pages 394-395

  Liu, Yu Ping ^a   Yu, Guang Rong ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; COLLAGEN TYPE 1; CYTOKINE; ENZYME; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

CARTILAGE CELL; CARTILAGE DEGENERATION; COLLAGEN DEGRADATION; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; KNEE LIGAMENT; LETTER; OSTEOARTHRITIS; OSTEOCLAST; OSTEOLYSIS; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; PROTEOGLYCAN SYNTHESIS; SYNOVIAL FLUID; SYNOVITIS; TISSUE INJURY;

ATHEROSCLEROSIS; CARTILAGE; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; OSTEOARTHRITIS;

EID: 72649102482     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.09.050     Document Type: Letter

References (14)

1. Wu Y.S., Hu Y.Y., Yang R.F., et al. The matrix metalloproteinases as pharmacological target in osteoarthritis: statins may be of therapeutic benefit. Med Hypotheses 69 (2007) 557-559
2. Hegemann N., Kohn B., Brunnberg L., et al. Biomarkers of joint tissue metabolism in canine osteoarthritic and arthritic joint disorders. Osteoarthritis Cartilage 10 (2002) 714-721
3. Yoshihara Y., Nakamura H., Obata K., et al. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in synovial fluids from patients with rheumatoid arthritis or osteoarthritis. Ann Rheum Dis 59 (2000) 455-461
4. Dai S.M., Shan Z.Z., Nishioka K., et al. Implication of interleukin 18 in production of matrix metalloproteinases in articular chondrocytes in arthritis: direct effect on chondrocytes may not be pivotal. Ann Rheum Dis 64 (2005) 735-742
5. Akasaki Y., Matsuda S., Nakayama K., et al. Mevastatin reduces cartilage degradation in rabbit experimental osteoarthritis through inhibition of synovial inflammation. Osteoarthritis Cartilage 17 (2009) 235-243
6. Lazzerini P.E., Capecchi P.L., Nerucci F., et al. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 63 (2004) 867-869
7. Dombrecht E.J., Van Offel J.F., Bridts C.H., et al. Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes. Clin Exp Rheumatol 25 (2007) 534-539
8. Staal A., Frith J.C., French M.H., et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 18 (2003) 88-96
9. Uzzan B., Cohen R., Nicolas P., et al. Effects of statins on bone mineral density: a meta-analysis of clinical studies. Bone 40 (2007) 1581-1587
10. Tousoulis D., Andreou I., Tentolouris C., et al. Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. Int J Cardiol (2009)
11. Zhang J., Bai S., Zhang X., et al. The expression of novel membrane-type matrix metalloproteinase isoforms is required for normal development of zebrafish embryos. Matrix Biol 22 (2003) 279-293
12. Alfredson H., Lorentzon M., Backman S., et al. CDNA-arrays and real-time quantitative PCR techniques in the investigation of chronic Achilles tendinosis. J Orthop Res 21 (2003) 970-975
13. Riley G.P., Curry V., DeGroot J., et al. Matrix metalloproteinase activities and their relationship with collagen remodelling in tendon pathology. Matrix Biol 21 (2002) 185-195
14. Tchetverikov I., Lohmander L.S., Verzijl N., et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis 64 (2005) 694-698